Given that the “blockbuster” drugs for the current treatment for T2DM, and now used for the treatment of obesity to induce weight loss, are GLP-1R agonists [93], it would be beneficial to understand the physiological role of basal GLP-1 in healthy humans in a metabolic state reflective of how we evolved, namely, euketonaemia MP1. Here, GCG is linked to obesity disorder.